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Abstract 
Background: In breast cancer patients receiving radiotherapy (RT), accurate target delineation and reduction of 
radiation doses to the nearby normal organs is important. However, manual clinical target volume (CTV) and organs-
at-risk (OARs) segmentation for treatment planning increases physicians’ workload and inter-physician variability 
considerably. In this study, we evaluated the potential benefits of deep learning-based auto-segmented contours by 
comparing them to manually delineated contours for breast cancer patients.
Methods: CTVs for bilateral breasts, regional lymph nodes, and OARs (including the heart, lungs, esophagus, spinal 
cord, and thyroid) were manually delineated on planning computed tomography scans of 111 breast cancer patients 
who received breast-conserving surgery. Subsequently, a two-stage convolutional neural network algorithm was 
used. Quantitative metrics, including the Dice similarity coefficient (DSC) and 95% Hausdorff distance, and qualitative 
scoring by two panels from 10 institutions were used for analysis. Inter-observer variability and delineation time were 
assessed; furthermore, dose-volume histograms and dosimetric parameters were also analyzed using another set of 
patient data.
Results: The correlation between the auto-segmented and manual contours was acceptable for OARs, with a mean 
DSC higher than 0.80 for all OARs. In addition, the CTVs showed favorable results, with mean DSCs higher than 0.70 
for all breast and regional lymph node CTVs. Furthermore, qualitative subjective scoring showed that the results 
were acceptable for all CTVs and OARs, with a median score of at least 8 (possible range: 0–10) for (1) the differences 
between manual and auto-segmented contours and (2) the extent to which auto-segmentation would assist physi-
cians in clinical practice. The differences in dosimetric parameters between the auto-segmented and manual con-
tours were minimal.
Conclusions: The feasibility of deep learning-based auto-segmentation in breast RT planning was demonstrated. 
Although deep learning-based auto-segmentation cannot be a substitute for radiation oncologists, it is a useful tool 
with excellent potential in assisting radiation oncologists in the future.
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Background
Modern radiotherapy (RT) planning is a complex process 
that relies on computed tomography (CT)-based three-
dimensional (3D) imaging as well as an expert team [1]. 
Based on CT simulations, radiation oncologists contour 
the relevant target volumes and surrounding normal 
structures and communicate with the dosimetrist the 
anticipated dosimetric goals that will deliver a therapeu-
tic radiation dose to the target while sparing the organs-
at-risk (OARs). In contrast to other primary malignancies 
such as lung and head & neck cancer, modern RT plan-
ning has not been not commonly applied to breast can-
cer, in which conventional formulaic field-based planning 
and two-dimensional techniques have been predomi-
nantly used [2].
Recently, as the use of comprehensive regional node 
RT is increasingly being supported by multiple land-
mark trials [3–6], the complexity of the target volume has 
also increased, and international guidelines for regional 
node irradiation have been developed [7, 8]. Although 
RT for breast cancer patients is known for its low rates 
of acute and late toxicity [9–11], studies have demon-
strated that incidental doses to the contralateral breast, 
esophagus, thyroid, and axillary-lateral thoracic vessel 
junction can affect patients’ quality-of-life [12–14]. Fur-
thermore, some studies have suggested that radiation-
induced damage to the lung and heart can even offset the 
benefit of loco-regional breast cancer RT [15]. However, 
quality issues and inter-physician variations of target vol-
umes and OAR contours have been of particular concern 
arising from dummy runs, multi-institutional studies, 
individual case reviews and audit studies [16–19]. Uncer-
tainties regarding volume delineation and subsequent 
target and normal tissue doses may not only decrease 
the treatment efficacy but also increase the complication 
risk.
With recent advances in computing power, algorithms, 
and data collection, artificial intelligence (AI) is increas-
ingly being used in healthcare to assist physicians. In 
radiation oncology, there are numerous areas in which 
AI is applicable, such as target and normal tissue seg-
mentation, dose optimization, decision support systems, 
application of predictive models, and quality assurance 
[20–22]. Auto-contouring tools have been adopted by 
an increasing number of physicians and have resulted 
in improved efficiency, particularly for OARs in head 
and neck cancer and target volume in prostate cancer 
[23, 24]. As there is a paucity of data regarding the auto-
segmentation of target volumes and OARs in breast RT 
planning, we attempted to train a deep learning-based 
auto-segmentation model for target volumes and OARs 




The study was approved by the institutional review 
board of Severance hospital (IRB: 4–2019-0339). It 
included 111 breast cancer patients who received adju-
vant RT after breast-conserving surgery (BCS). Both 
left-sided and right-sided breast cancer patients were 
included. The median age of the patients was 51  years 
(range 28–77  years), and the median body mass index 
was 22.5  kg/m2 (range 17.03–35.4  kg/m2). For T stage, 
15 patients were Tis (14%), 60 patients were T1 (54%), 
33 patients were T2 (30%), and 3 patients were T3 (3%). 
For N stage, 82 patients were N0 (74%), 26 patients 
were N1 (23%), and 3 patients were N2 (3%). RT field 
included whole breast (WB) only for 79 patients (71%), 
whereas it included the WB with regional lymph nodes 
for 32 patients (29%). Both non-contrast (n = 50) and 
contrast-enhanced (n = 61) planning CT scans were 
used for manual delineation of CTVs and OARs. Plan-
ning CT scan (Somatom Sensation Open syngo CT 
2009E, Siemens and Aquilion TSX-201A, Toshiba) was 
performed approximately two weeks prior to RT with 
a CT slice thickness of 3 mm. The setup position for all 
planning CT scans was the supine position with both 
arms held up using an arm support device (CIVICO). 
Contrast-enhanced planning CT was performed 1  min 
after administration of 80–90  mL intravenous contrast 
(iohexol, 84.11  g / 130  mL; depending on the patient’s 
weight).
Delineation
Previous contours used for patient treatment were not 
used in this study. For homogeneity, a single expert who 
is ESTRO teaching course certified and treats approxi-
mately 550 breast cancer patients per year contoured the 
CTVs and OARs within 1 month, with the patients’ clini-
cal information blinded. The target volume consisted of 
CTVs of right and left breasts (CTVp_breast); axillary 
Trial registration Retrospectively registered.
Keywords: Breast cancer, Auto-segmentation, Deep learning, Clinical target volume, Organs-at-risk
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levels 1, 2, and 3 (CTVn_L1, L2, L3); internal mammary 
chain (CTVn_IMN); and lymph node level 4 (CTVn_
L4), which is supraclavicular lymph node delineated 
according to the ESTRO guidelines [7]. In our study, we 
included interpectoral nodes mentioned in the ESTRO 
guidelines in CTVn_L2. In addition, the supraclavicu-
lar lymph nodes were additionally delineated according 
to the RTOG guidelines (CTVn_SCL RTOG) [25]. The 
OARs included the heart, right and left lungs, esophagus, 
spinal cord, and thyroid [26].
Deep learning‑based auto‑segmentation
To segment the CTVs and OARs, a 3D U-Net-like con-
volutional neural network (CNN) was used, which was 
based on U-Net structure [27], and combined with 
3D version of EfficientNet-B0 as the backbone (Fig.  1) 
[28]. In the CNN, instead of using 2D operations as in 
U-Net and EfficientNet, their 3D counterparts are used 
to exploit the 3D structural information. For inputs of 
the CNN, all cases were resampled to a voxel spacing of 
1.0 × 1.0 × 3.0 mm3 and then the image intensity values 
of a truncated range of [-160, 240] were linearly nor-
malized into the range of [0, 1]. Owing to GPU memory 
limitations, the CNN was trained in the patch level, spe-
cifically, input the 3D patch with a size of 128 × 128 × 64 
from the volumetric CT images and output the 3D patch 
of multi-label segmentation. Furthermore, we trained the 
CNN with the sum of cross-entropy and dice loss, and 
set the optimizer to be RMSprop with an initial learn-
ing rate of 5 × 10–4. During training, in order to reduce 
overfitting and improve generalization, we employed 
regularization of weight decay of 10–4 [29], and data aug-
mentation techniques such as scaling, flip, and rotation 
to all training patches.
Analysis
Among the 111 cases that were newly contoured by an 
expert, 92 cases were used as the training dataset, and 
19 cases were used as test dataset #1 (contrast: 10 cases; 
non-contrast: 9 cases) for the analysis of the quantita-
tive metrics. Test dataset #2 was prepared separately to 
analyze the efficacy of auto-segmented contours using 
real-world heterogeneous data. Dosimetric parameters 
were analyzed using different sets of CT scans with 
manual contours (previously used for patient treat-
ment) delineated by various physicians and RT plans 
of breast cancer patients who received RT after surgery 
(n = 42).
Both quantitative metrics and qualitative scoring were 
used for analyzing test dataset #1. Quantitative metrics 
included the most commonly used geometrical indices, 
such as Dice similarity coefficient (DSC) and 95% Haus-
dorff distance (HD), to compare the auto-segmented 
and manually delineated contours. DSC is a measure of 
overlap between two contours, from “0” to “1,” where “1” 
indicates a complete overlap. HD is the measure of dis-
tance between two contours, where 0  mm indicates a 
complete overlap. For qualitative scoring, two panels—an 
expert breast cancer radiation oncologist panel (n = 11) 
and a non-expert panel that included residents and radia-
tion oncologists whose specialty is not breast cancer 
(n = 15)—from 10 institutions answered the following 
questions after watching an example video on manual 
contouring and auto-segmentation contouring on a plan-
ning CT scan:
1. What score would you give for the differences 
between manually delineated contours and auto-seg-
mentation contours? (Difference scores)
i. Answer: 0 (most different) to 10 (least different)
2. How much do you think auto-segmentation would 
assist you in real-world clinical practice? (Assistance 
scores)
i. Answer: 0 (not helpful) to 10 (very helpful)
To analyze test dataset #2, auto-segmented contours 
were generated in 42 patients’ CT scans, and dose-
volume histograms were analyzed using both auto-
segmented contours and original manual contours. 
Furthermore, dosimetric analysis was performed by com-
paring the mean dose (Gy),  D0.03cc (Gy), and  V5Gy (cc) for 
heart; mean dose (Gy),  V20Gy, (%), and  V5Gy (%) for ipsi-
lateral lung; mean dose for contralateral lung;  D0.03cc (Gy) 
for esophagus; and  D1cc (Gy) for spinal cord for the man-
ual and auto-segmented contours.
Additionally, inter-user variability was assessed by ana-
lyzing the DSCs and HDs of contours delineated by three 
Fig. 1 Schematic of the proposed convolutional neural network 
architecture (U-Net with EfficientNet-B0)
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different radiation oncologists on a randomly selected 
CT scan of a breast cancer patient. Furthermore, the con-
touring time was recorded for all three radiation oncolo-
gists to compare the time taken for manual delineation 
with that for auto-segmentation. These results for inter-
user variability are included as Additional file 1.
Results
Quantitative metrics
Examples of deep learning-based auto-segmentation and 
manual contours are shown in Fig.  2 and as a video in 
Additional file  2. Table  1 compares the auto-segmented 
contours and manual contours for OARs and CTVs using 
Fig. 2 Example of deep learning-based auto-segmentation (green) and manual (red) contours
Table 1 Comparison of  deep learning auto-segmentation and  manual contours of  organs-at-risk and  target volumes 
using test dataset #1
Total (n = 19) Contrast (n = 10) Non‑contrast (n = 9)
DSC STD 95% HD (mm) STD (mm) DSC STD 95% HD (mm) STD (mm) DSC STD 95% HD (mm) STD (mm)
Organs-at-risk
 Heart 0.95 0.02 4.56 2.33 0.96 0.01 3.83 2.80 0.94 0.02 5.36 1.27
 Rt Lung 0.98 0.01 3.61 2.15 0.98 0.00 4.64 2.46 0.97 0.01 2.46 0.69
 Lt Lung 0.97 0.01 2.82 0.71 0.97 0.01 3.04 0.76 0.97 0.02 2.59 0.55
 Thyroid 0.89 0.05 1.88 0.90 0.90 0.04 1.55 0.65 0.88 0.05 2.25 0.99
 Esophagus 0.84 0.06 2.87 1.49 0.85 0.05 2.47 0.91 0.83 0.07 3.31 1.85
 Spinal cord 0.82 0.10 2.98 3.10 0.87 0.07 1.58 0.74 0.76 0.10 4.54 3.89
Target
 CTVp_breast 0.94 0.04 5.50 3.17 0.94 0.04 5.13 2.74 0.94 0.04 5.91 3.55
 CTVn_L1 0.74 0.08 10.93 6.27 0.71 0.09 13.51 7.10 0.78 0.05 8.07 3.40
 CTVn_L2 0.80 0.07 6.36 2.52 0.79 0.07 6.71 2.40 0.81 0.06 5.98 2.60
 CTVn_L3 0.64 0.13 7.99 3.81 0.66 0.10 6.97 2.87 0.62 0.16 9.11 4.37
 CTVn_IMN 0.72 0.09 5.75 3.36 0.67 0.09 7.53 3.71 0.77 0.07 3.77 1.00
 CTVn_L4 0.74 0.12 6.04 6.12 0.67 0.12 8.37 7.61 0.80 0.09 3.45 1.41
 CTVn_SCL RTOG 0.78 0.08 6.95 2.89 0.76 0.08 7.85 3.20 0.80 0.08 5.95 2.09
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mean DSC and 95% HD. With regard to OARs, the mean 
DSCs were above 0.80, and mean 95% HDs were below 
5 mm, which are acceptable results. For CTV, the correla-
tion between the auto-segmented and manual contours 
was excellent for the breast, with a mean DSC higher 
than 0.90. As for other CTVs, including CTVn_L1, L2, 
L3, CTVn_IMN, CTVn_L4, and CTVn_SCL RTOG, the 
mean DSCs were mostly higher than 0.70. The mean 
95% HD ranged from 5.50 to 10.93  mm for CTVs. The 
mean DSCs and 95% HDs did not show a large difference 
between the contrast-enhanced CT test datasets and 
non-contrast CT test datasets.
Dosimetric analysis
Figures  3a and b show dose-volume histograms with 
average dosimetric values for patients who received WB 
RT only or that with regional node irradiation, respec-
tively. The increase at the end for the ipsilateral breast 
contour line in the dose-volume histograms is due to the 
initial RT plan that included a simultaneous integrated 
boost for the tumor bed. As shown in Fig. 3a, most man-
ual and auto-segmented contours were similar, except for 
a minor difference for the spinal cord. The difference in 
the delineated spinal cord volume (average absolute dif-
ference of 7.24 ± 9.07cc) may have affected the results. 
Figure 3b shows that there was a considerable difference 
in the coverage for regional nodal contours such as axil-
lary lymph node levels 1, 2, 3, and IMN.
In addition, various dosimetric parameters for OARs—
such as heart, lung, esophagus, and spinal cord—were 
analyzed, as shown in Table 2. The mean absolute differ-
ences for all parameters were minimal, showing the effi-
cacy of auto-segmented contours.
Qualitative scoring
To confirm whether deep learning-based auto-segmenta-
tion can practically serve as a useful tool in clinical prac-
tice, qualitative scores were also analyzed. Qualitative 
scoring was performed by both an expert (n = 11) and a 
non-expert panel (n = 15) for difference and assistance 
scores, as shown in Fig. 4. For OARs, the median differ-
ence score was 9 (range 8–10), and the median assistance 
score was 9 (range 8–10), in the case of the expert panel. 
The scores were similar for OARs in the case of the non-
expert panel, with a median difference score of 8 (range 
6–10) and a median assistance score of 9 (range 8–10). 
For the CTVs of breasts and regional lymph nodes, 
the median difference score was 8 (range 7–9), and the 
median assistance score was 9 (range 7–10), in the case 
of the expert panel. With regard to the non-expert panel, 
the median difference score was 8 (range 6–10), and the 
median assistance score was 9 (range 5–10).
Analyses for inter-observer variability and contouring 
time are included in Additional file 1.
Discussion
In this study, we trained a deep learning-based frame-
work to segment 14 CTVs and six OARs in simulation 
CT images for breast cancer RT. Our findings suggest 
that the proposed algorithm performed well, exhibit-
ing good agreement with the CTVs and OARs that were 
manually contoured by clinical experts from both quali-
tative and quantitative aspects. The dosimetric implica-
tions of the auto-contours were also evaluated, and we 
did not observe any significant difference in dose-volume 
histograms between the auto-segmented contours and 
manual contours.
Although AI solutions are best suited to situations in 
radiology where ground truths are clear, the concept 
of a ground truth in RT fields is disputable because RT 
is both a science and an art entailing clinical input and 
creativity [30]. More specifically, inter-physician varia-
tions are present even in contours delineated by board-
certified radiation oncologists from the same institution 
(e.g., variations in the nodal target volumes in our study; 
Additional file  1). We acknowledge that the generation 
of the same contours by an AI algorithm under multiple 
scenarios does not mean that the generated contours are 
optimal. Considering this, we collected data based on the 
assumption that the international guidelines are an alter-
native ground truth [7, 8]. Although the proposed algo-
rithm performed well, a risk exists that its reliability may 
decrease in some situations [31].
In 2006, Eldesoky et al. first reported the clinical util-
ity of atlas-based auto-segmentation (ABAS) in loco-
regional RT for breast cancer using the data of 60 
patients, where delineation was performed according to 
the ESTRO consensus guideline [32]. ABAS showed good 
agreement in some volumes (e.g., lung, heart, and breast), 
whereas it showed only modest agreement in other struc-
tures or in external datasets. However, research inter-
est shifted to deep learning-based auto-segmentation 
because ABAS had several limitations; thus, we recently 
published a study comparing the performance of deep 
learning-based auto-segmentation with that of two com-
mercially available ABAS systems for breast cancer RT 
[33]. In this study, the deep learning-based approach 
showed more consistent and robust performance than 
ABAS for most structures, and this performance gap 
increased substantially for soft-tissue-based regions and 
smaller volumes.
Deep learning-based auto-segmentation has been 
widely investigated in head & neck, lung, and prostate 
cancers and has demonstrated clinically relevant impact 
with regard to saving time and mitigating inter-observer 
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Fig. 3 Comparison of dose-volume histograms with average dosimetric values of manual contours (solid line) and auto-segmentation contours 
(dotted line) for patients who received whole breast RT only(a) or that with regional node irradiation (b). (Abbreviations: SCL, supraclavicular lymph 
nodes; IMN, internal mammary lymph nodes; AXL3, axillary lymph node level 3; AXL2, axillary lymph node level 2; AXL1, axillary lymph node level 1)
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Table 2 Dosimetric outcomes for maual and auto-segmented contours for test dataset #2 (n = 42)
Manual Autocontour Absolute difference
Mean STD Mean STD Mean STD
Heart
 Mean (Gy) 3.27 1.10 3.26 1.10 0.08 0.07
 D0.03cc (Gy) 22.72 10.24 21.75 9.68 1.51 1.76
 V5Gy (cc) 16.08 10.23 16.13 10.39 0.73 0.75
Lung
 Ipsilateral lung mean (Gy) 6.87 0.97 6.82 0.97 0.11 0.18
 Ipsilateral lung  V20Gy (%) 10.08 2.59 9.82 2.68 0.36 0.35
 Ipsilateral lung  V5Gy (%) 35.25 5.15 35.46 5.32 0.67 0.98
 Contralateral lung mean (Gy) 1.83 0.66 1.84 0.67 0.02 0.03
Esophagus
 D0.03cc (Gy) 7.82 5.16 7.56 4.73 0.85 1.61
Spinal cord
 D1cc (Gy) 4.38 2.69 4.37 2.96 0.43 1.08
Fig. 4 Qualitative scoring by expert panel (n = 11) and non-expert panel (n = 15) for difference and assistance scores
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variability [23, 24, 34]. Although several studies have 
reported the feasibility of the deep learning-based 
approach for the breast, training and testing has only 
been performed for ipsilateral breast CTVs [35, 36]. In 
this study, a satisfactory DSC of 0.94 for CTVp_breast 
was shown, which is similar to that obtained for other 
series using the deep learning-based approach. One study 
using a dataset of 800 patients with a deep learning algo-
rithm (DD-ResNet) showed a mean DSC of 0.91 for the 
CTVs of both breasts [35]. Furthermore, similar to the 
study by Eldesoky et al. [32], in which they tested ABAS, 
we performed training not only for WB CTVs but also 
for various OARs and other CTVs, including regional 
lymph nodes in breast cancer patients. The current deep 
learning-based auto-segmentation model showed higher 
performance in segmenting various OARs—including 
heart, lung, thyroid, esophagus, and spinal cord—that 
were fairly large and well-defined. As for regional lymph 
nodes, because of the smaller volumes and less well-
defined borders, the current model exhibited modest 
performance. Regarding qualitative scoring, the expert 
and non-expert panels gave high difference and assis-
tance scores for both the OARs and CTVs.
To date, even with fully validated auto-segmentations, 
modification or correction by clinical experts is com-
monly accepted. However, whether modification or cor-
rection is essential when auto-contours are utilized for 
dosimetric analysis has not been well studied. In this 
study, dosimetric analysis showed that there was a good 
agreement in dose distribution between manual and 
auto-segmented contours for OARs. However, as for 
CTVs, particularly for the axillary lymph node regions 
and IMN, there were some discrepancies between man-
ual and auto-segmented contours. For OARs, the use 
of auto-segmented contours for dose–response related 
studies or for predicting in-clinic normal tissue com-
plication probabilities could be proposed. However, for 
CTVs, it is apparent that auto-contours in target volumes 
require significant modification by experts to conform to 
the corresponding anatomy and to individualize accord-
ing to tumor and patient information. In the research 
field, auto-segmented CTVs could be used as a reference 
point while comparing the target volume delineation of 
various participants.
In breast cancer trials, variations in target delineation 
and RT planning have become a prominent issue, par-
ticularly in multidisciplinary trials that lack RT quality 
assurance programs [37]. In a recent audit study across 
a large network, it was found that nodes were not con-
toured or the contour quality was inadequate for 18% of 
patients [38]. In a Korean study that investigated inter-
institutional variations in breast intensity-modulated RT 
(KROG 19–01), there were large heterogeneities in the 
target volume as well as OARs, producing large variations 
in mean heart dose and lung  V20Gy (up to five times in the 
same dummy run case). We believe that our auto-seg-
mented contours of CTVs and OARs can play an impor-
tant role in the breast RT quality assurance process, as 
illustrated by Chen et al. [36]. Nationwide quality assur-
ance is underway in Korea with our proposed algorithm.
Accurate delineation of all OARs and CTVs is a labo-
rious task; here, auto-segmentation can serve as a useful 
tool in reducing the workload of physicians. In a previ-
ous study on ABAS for loco-regional RT of breast can-
cer, it was found that ABAS reduced the time required 
for manual segmentation before correction by 93% and 
after correction by 32% [32]. This study showed a simi-
lar potential, with average times of 39  min and 10  min 
for manual delineation and deep learning-based auto-
segmentation, respectively (Additional file  1). With the 
assistance of deep learning-based auto-segmentation, 
radiation oncologists will be able to work more effi-
ciently. Qualitative subjective scoring by the expert and 
non-expert panels exhibited satisfactory results for both 
difference and assistance scores, showing that deep 
learning-based auto-segmentation can serve as a helpful 
tool in real-world clinics.
This study has several limitations. First, the manual 
contours used as reference were delineated by a single 
expert radiation oncologist, which can be considered 
both as a strength and a limitation. As a single expert 
delineated all contours, we were able to train the deep 
learning-based model sufficiently with homogenous data 
involving fewer patients compared to other studies. How-
ever, in the real world, inter-observer variations exist, and 
there is no 100% gold standard. Thus, we plan to conduct 
further studies using contours from multiple experts 
for generalization. However, in a study comparing deep 
learning-based auto-segmentation of OARs and CTVs 
based on expert inter-observer variability in RT planning, 
the accuracy of deep learning-based auto-segmented 
contours trained using data derived from a single expert 
was comparable to that of the contours obtained using 
data with inter-observer variability, thereby showing that 
the results of the current study with the contours of a sin-
gle expert radiation oncologist are still meaningful [39].
The second limitation of our study is the number of 
patients analyzed. However, as mentioned earlier, the 
DSC for CTVp_breast was better in our study compared 
to that in other studies. Furthermore, quantitative met-
rics were not analyzed for test dataset #2 owing to the 
heterogeneity of the initial contour volumes. Another 
limitation of our study would be that the position of the 
patients during CT simulation and treatment may vary 
among institutions. In addition, different clinical situa-
tions, such as post-mastectomy status and reconstructed 
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status, exist for breast cancer patients. In the near future, 
we plan to validate our deep learning model with data 
from other institutions. Even with the current results, 
we are efficiently using auto-segmentation in the clinic 
by directly sending the CT simulation images to the 
server after simulation, and the physician uses the auto-
segmented contours for RT planning afterwards. How-
ever, further research with a larger number of patients is 
required. Currently, we are engaged in a national multi-
center study aimed at validating the results presented 
herein and leveraging AI techniques to improve the qual-
ity of intensity-modulated RT for breast cancer patients 
(KROG 21–01).
Additionally, it would have been more favorable if coro-
nary vessels were included as an OAR. The importance of 
cardiac substructures, such as coronary vessels, is being 
increasingly acknowledged [40]. Currently, the develop-
ment of a separate deep learning-based auto-segmenta-
tion model focused on cardiac substructures, including 
the right atrium, right ventricle, left atrium, left ventricle, 
right coronary artery, and left anterior descending artery, 
is underway.
Conclusions
This study demonstrated the potential and feasibility of 
deep learning-based auto-segmentation for breast cancer 
patients who are receiving RT after BCS. Although deep 
learning-based auto-segmentation cannot serve as a sub-
stitute for the experience of radiation oncologists, it has 
the potential to serve as a useful tool in assisting them.
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